Characterisation of the antidepressant properties of nitric oxide synthase inhibitors in the olfactory bulbectomised rat model of depression
暂无分享,去创建一个
Thomas J. Connor | Jennifer Rouine | Christian Kerskens | T. Connor | C. Kerskens | Andrew Harkin | Valentina Gigliucci | Shane Gormley | Sinead Gibney | A. Harkin | S. Gormley | S. Gibney | V. Gigliucci | J. Rouine | Valentina Gigliucci
[1] B. Leonard,et al. The olfactory bulbectomised rat as a model of depression , 2005, Neuroscience & Biobehavioral Reviews.
[2] Nanxin Li,et al. mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.
[3] Kyooseob Ha,et al. Inhibitory effect of the antidepressant imipramine on NF-κB-dependent CXCL1 expression in TNFα-exposed astrocytes. , 2012, International immunopharmacology.
[4] Carlos A. Zarate,et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.
[5] B. Leonard,et al. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. , 1981, International review of neurobiology.
[6] Steven C. R. Williams,et al. The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques , 2003, Brain Research.
[7] L. Eng,et al. GFAP and Astrogliosis , 1994, Brain pathology.
[8] P. K. Moore,et al. Effects of selective inhibitors of neuronal nitric oxide synthase on carrageenan-induced mechanical and thermal hyperalgesia , 1998, Neuropharmacology.
[9] C. Zarate,et al. Ketamine and the next generation of antidepressants with a rapid onset of action. , 2009, Pharmacology & therapeutics.
[10] A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity , 2008 .
[11] A. Simmons,et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. , 2011, Archives of general psychiatry.
[12] James M. O'Donnell,et al. A study of VitalView™ for behavioural and physiological monitoring in laboratory rats , 2002, Physiology & Behavior.
[13] Christian M Kerskens,et al. Quantitative Functional Magnetic Resonance Imaging of Brain Activity Using Bolus-Tracking Arterial Spin Labeling , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[14] A. Becker,et al. Cell Proliferation is Influenced by Bulbectomy and Normalized by Imipramine Treatment in a Region-Specific Manner , 2006, Neuropsychopharmacology.
[15] M. Bourin,et al. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice , 2003, Behavioural Brain Research.
[16] Christoph W. Blau,et al. Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP , 2012, Neurobiology of Aging.
[17] Christoph W. Blau,et al. The age-related deficit in LTP is associated with changes in perfusion and blood-brain barrier permeability , 2012, Neurobiology of Aging.
[18] Christoph W. Blau,et al. Bolus-tracking arterial spin labelling: theoretical and experimental results , 2009, Physics in medicine and biology.
[19] R. Koehler,et al. Astrocytes and the regulation of cerebral blood flow , 2009, Trends in Neurosciences.
[20] Marcus E Raichle,et al. Glucose metabolism in the amygdala in depression: Relationship to diagnostic subtype and plasma cortisol levels , 2002, Pharmacology Biochemistry and Behavior.
[21] F. Franconi,et al. An in-vivo magnetic resonance imaging study of the olfactory bulbectomized rat model of depression , 2000, Brain Research.
[22] Mathias Hoehn,et al. MRI Detection of Secondary Damage After Stroke: Chronic Iron Accumulation in the Thalamus of the Rat Brain , 2008, Stroke.
[23] J. Kelly,et al. A review of the relevance and validity of olfactory bulbectomy as a model of depression , 2003, Clinical Neuroscience Research.
[24] J. Kelly,et al. Behavioural and Neurochemical Effects of Dizocilpine in the Olfactory Bulbectomized Rat Model of Depression , 1997, Pharmacology Biochemistry and Behavior.
[25] G. B. Wisely,et al. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. , 1994, Journal of immunology.
[26] S. Kulkarni,et al. Nitric oxide and major depression. , 2011, Nitric oxide : biology and chemistry.
[27] M. Raichle,et al. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.
[28] R. Duman,et al. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents , 2012, Trends in Neurosciences.
[29] Klaus P. Ebmeier,et al. Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses , 2012, European Neuropsychopharmacology.
[30] M. Doucet,et al. Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice , 2013, Neuropsychopharmacology.
[31] P. Skolnick,et al. Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.
[32] Susumu Mori,et al. Structural insights into the rodent CNS via diffusion tensor imaging , 2012, Trends in Neurosciences.
[33] Andrew M Blamire,et al. Acute Astrocyte Activation in Brain Detected by Mri: New Insights into T1 Hypointensity , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[34] S. Moncada,et al. Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.
[35] T. Connor,et al. MDMA ("Ecstasy") suppresses the innate IFN-gamma response in vivo: a critical role for the anti-inflammatory cytokine IL-10. , 2007, European journal of pharmacology.
[36] M. Banasr,et al. Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like Behaviors , 2008, Biological Psychiatry.
[37] M. Furey,et al. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression , 2008, Brain Structure and Function.
[38] J. Kelly,et al. Chronic Fluoxetine Treatment Attenuates Stressor-Induced Changes in Temperature, Heart Rate, and Neuronal Activation in the Olfactory Bulbectomized Rat , 2007, Neuropsychopharmacology.
[39] S. Chaki,et al. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression , 2011, Behavioural Brain Research.
[40] C. Ouimet,et al. Altered dendritic spine density in animal models of depression and in response to antidepressant treatment , 2001, Synapse.
[41] G. Rajkowska,et al. Depression: What We can Learn from Postmortem Studies , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[42] J. Kelly,et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. , 1999, European journal of pharmacology.
[43] F. X. Guix,et al. The physiology and pathophysiology of nitric oxide in the brain , 2005, Progress in Neurobiology.
[44] E. Bora,et al. Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. , 2012, Journal of affective disorders.
[45] B. Ravnkilde,et al. Hippocampal volume and depression: a meta-analysis of MRI studies. , 2004, The American journal of psychiatry.
[46] Guang Chen,et al. Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.
[47] S. Goyal,et al. Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: Involvement of NPY Y1 receptors , 2009, Brain Research.
[48] G. Sanacora,et al. Beyond Monoamines: Glutamatergic Function in Mood Disorders , 2005, CNS Spectrums.
[49] Dost Öngür,et al. Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders , 2010, Biological Psychiatry.
[50] Yogesh K. Dwivedi,et al. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. , 2013, Current pharmaceutical design.
[51] J. Kelly,et al. The olfactory bulbectomized rat as a model of depression: an update. , 1997, Pharmacology & therapeutics.
[52] A. Harkin,et al. A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test , 2010, Pharmacology Biochemistry and Behavior.
[53] A. Villringer,et al. Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. , 2012, Journal of affective disorders.
[54] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[55] Bin Wang,et al. Neuronal nitric oxide synthase contributes to chronic stress‐induced depression by suppressing hippocampal neurogenesis , 2007, Journal of neurochemistry.
[56] J. Qu,et al. Protective effects of imipramine in murine endotoxin-induced acute lung injury. , 2010, European journal of pharmacology.
[57] R. Kalisch,et al. Anxiety and Hippocampus Volume in the Rat , 2006, Neuropsychopharmacology.
[58] R. Oosting,et al. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. , 2009, European journal of pharmacology.
[59] K. Suk,et al. NF-κB as a common signaling pathway in ganglioside-induced autophagic cell death and activation of astrocytes , 2010, Journal of Neuroimmunology.
[60] C. Belzung,et al. Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice , 2009, Pharmacology Biochemistry and Behavior.
[61] H. Zeumer,et al. MRI abnormalities in normal‐appearing brain tissue of treated adult PKU patients , 2008, Journal of magnetic resonance imaging : JMRI.